Biopharma company Halozyme Therapeutics is on a mission to replace IV-drug delivery. It develops subcutaneous devices to make it easier and quicker to inject high-volume drugs into patients. Halozyme ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...